GSK plc (NYSE:GSK) Shares Acquired by Creative Planning

Creative Planning boosted its position in shares of GSK plc (NYSE:GSK) by 3.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 211,100 shares of the pharmaceutical company’s stock after purchasing an additional 7,854 shares during the period. Creative Planning’s holdings in GSK were worth $8,630,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Register Financial Advisors LLC acquired a new stake in GSK during the 1st quarter valued at $31,000. Ashton Thomas Private Wealth LLC acquired a new position in GSK during the 2nd quarter worth $37,000. PrairieView Partners LLC acquired a new position in GSK during the 2nd quarter worth $47,000. Triad Wealth Partners LLC acquired a new position in GSK during the 2nd quarter worth $49,000. Finally, Concord Wealth Partners grew its holdings in GSK by 69.7% during the 1st quarter. Concord Wealth Partners now owns 1,436 shares of the pharmaceutical company’s stock worth $62,000 after acquiring an additional 590 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 10.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Barclays upgraded shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. Jefferies Financial Group lifted their price objective on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, GSK has an average rating of “Buy” and an average price target of $50.00.

GSK Stock Down 0.4 %

GSK stock opened at $38.00 on Wednesday. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The company has a market capitalization of $78.75 billion, a price-to-earnings ratio of 13.77, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The firm’s 50-day moving average is $41.33 and its two-hundred day moving average is $41.21. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. The company had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. On average, analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were paid a $0.3843 dividend. The ex-dividend date was Friday, August 16th. This represents a $1.54 annualized dividend and a dividend yield of 4.05%. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s payout ratio is currently 55.80%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.